The Government of India has extended the application deadline for its ambitious ₹5,000-crore Promotion of Research & Innovation in Pharma-MedTech (PRIP) scheme, offering more time to companies, startups and research institutions to register and submit proposals. The decision, taken by the Department of Pharmaceuticals, aims to ensure that the scheme attracts maximum participation from innovators across the country.
Officials explained that while the initial response was promising, several applicants sought extra time to complete formalities such as online registration, payment through Bharatkosh, and documentation.The government hopes that the extension will lead to a more inclusive and better-prepared pool of applicants rather than rushed submissions.
From “pharmacy” to “laboratory” of the world
India’s pharmaceutical sector has long been recognised as the “pharmacy of the world”, known for producing affordable generic drugs and vaccines. However, when it comes to innovation, the numbers tell a different story. Indian pharmaceutical companies spend around 7% of their revenues on R&D, while global leaders invest between 15 and 20%. The PRIP scheme aims to close this gap by steering the industry toward discovery, design and deep research.
The total allocation of ₹5,000 crore will be spread over six years (FY 2023–24 to FY 2029–30).This funding is expected to accelerate the development of new chemical entities (NCEs), biologics, biosimilars, complex generics, orphan drugs, medical devices, and antimicrobial resistance (AMR) solutions.
Also Read: Startup Sets Out to Mine ‘Moon Fuel’ Worth $20 Million a Kilo
Inside PRIP: How the scheme works
The PRIP scheme has two major components:-
- Component A – About ₹700 crore is dedicated to building Centres of Excellence (CoEs) in seven branches of the National Institute of Pharmaceutical Education and Research (NIPER). These centres will strengthen India’s research infrastructure, provide advanced laboratories, and train skilled scientists.
- Component B – The remaining ₹4,200–₹4,250 crore is reserved for industry-academia collaborations, startups, and established pharmaceutical and MedTech companies. These funds will support R&D projects in areas with high public-health relevance or innovation potential.
The scheme allows up to ₹5 crore for early-stage projects, particularly those led by startups or MSMEs. For advanced or late-stage projects, the financial support can reach up to ₹100 crore, depending on project scale, innovation depth and feasibility. Strategic Priority Innovations, such as drugs for rare diseases or AMR, can receive an even higher share of support, given their limited commercial viability but strong social importance.
Why was the deadline extended?
The extension was driven by both administrative and strategic factors. The online application process involves entity registration, digital verification, and multiple documentation stages that take time to complete. Smaller firms and academic partners had raised concerns that the initial timelines were too tight.
Beyond the paperwork, the government recognised that quality proposals take time. Since PRIP is designed for high-impact, research-intensive projects, allowing more time means applicants can refine technical details, build collaborations and align intellectual-property or regulatory strategies.
Catalysing innovation at scale
By funding innovation rather than mere production, PRIP represents a turning point in India’s healthcare strategy. The scheme’s intent is clear, to push India up the global value chain from low-cost producer to high-value innovator.
Today, India accounts for roughly 3.4% of global pharmaceutical sales despite being a dominant supplier of generics. The government hopes that deeper R&D and intellectual-property creation can lift this share to 4–5% over the coming decade. Beyond exports, this shift is expected to generate high-skill jobs, reduce dependence on imported medical devices and active ingredients, and improve national health security.
Industry optimism with a dose of realism
The PRIP initiative has been generally well-received by industry experts. They see it as a crucial step in closing the long-standing R&D divide between Western and Indian businesses. Though significant, most people concur that ₹5,000 crore by itself is not transformative. Developing one breakthrough drug can cost billions of dollars and take over a decade, so the scheme’s immediate impact will likely be catalytic rather than revolutionary.
Analysts expect the programme to strengthen translational research, help firms de-risk early-stage projects, and encourage collaboration between academia and industry. The real success will depend on the effectiveness of fund distribution, the rigour of project selection, and the speed of execution once grants are approved.
What the extension means for applicants
The new deadline is a great chance for innovators. During this period, research institutions and startups can fortify their proposals, form partnerships, and make sure that all eligibility requirements are met. Additionally, the extension shows that the government is paying attention to industry concerns and wants to promote involvement rather than exclusion.
It represents a developing policy environment for the larger ecosystem, one that prioritises careful planning, teamwork, and excellent research over hasty but insufficient submissions.
India’s pharmaceutical story may change from one of imitation to one of innovation thanks to the PRIP scheme. Extending the deadline demonstrates a desire to make the process more inclusive and significant, not just a procedural change.
However, the real test will lie in implementation, transparent fund allocation, milestone-based monitoring, and support for commercialisation once research delivers results. If executed with vision and consistency, PRIP could help India evolve from being the “pharmacy of the world” to truly becoming the “laboratory of the world.”
Also Read: How One Woman Left Corporate India to Build a ₹10 Crore Saree Brand
